PITTSBURGH—In more good news for veterans who have received treatment for hepatitis C virus, VA researchers have found that treatment not only reduces the risk of complications from liver disease, it also dramatically reduces the... View Article
ANN ARBOR, MI—New prognostic models developed by VA researchers can help clinicians identify which patients who have or have had chronic hepatitis C virus infection will develop cirrhosis or hepatocellular carcinoma. While the VA has... View Article
New cases of acute and chronic hepatitis C (HCV) have dropped sharply among U.S. servicemembers since 2008, bucking the nationwide trend.
VA researchers expect complications from chronic hepatitis C virus (HCV) in women veterans to continue to rise for a decade or longer after rates begin to decline in men.
PORTLAND, OR—Hepatitis C virus (HCV) infection is linked to diabetes and often worsens glycemic control in patients with diabetes. A study published in Diabetes Care investigated whether eradication of HCV infection with direct-acting antiviral (DAAs)... View Article
HOUSTON—The epidemiology clinical course of hepatitis C virus (HCV) infection is affected by gender. Yet, few long-term longitudinal studies have examined trends in the incidence and prevalence of serious liver complications among women compared with... View Article
Over the next year or so, the remarkable transformation of hepatitis C (HCV) treatment at the VA will likely reach some type of equilibrium, a new study suggested.
Hepatitis C virus (HCV) infection is known to cause hepatocellular carcinoma (HCC) and subtypes of non-Hodgkin lymphoma (NHL).
For the VA, the combination of effective treatment options and much lower prevalence of HCV in younger veterans may offer a light at the end of the tunnel — and a turning point in the steady rise of HCV-associated complications such as cirrhosis and hepatocellular carcinoma (HCC) in only a few years.
VA Suggests High Price Could Be Offset Future Savings
By Brenda L. Mooney BOSTON – Rates of serologic testing for hepatitis B (HBV) at the VA fail to meet levels recommended by the American Association for the Study of Liver Diseases (AASLD) practice guideline,... View Article
By Annette M. Boyle WASHINGTON – While commercial insurers responded to the approval of the breakthrough drug sofosbuvir for hepatitis C (HCV) by implementing prescribing restrictions, limiting use to the sickest patients and charging higher... View Article
By Stephen Spotswood WASHINGTON – When the first Infectious Disease Clinic took place at the Washington, DC, VAMC in 1985, only a handful of HIV-infected patients took advantage. In fact, the disease hadn’t even been... View Article
By Brenda L. Mooney PITTSBURGH – Will hepatitis C become a rare disease over the next two decades or so? The answer is yes, according to a computer simulation conducted by the University of Pittsburgh... View Article
By Annette M. Boyle Jeffery McCombs, PhD LOS ANGELES — While achieving undetectable viral loads reduces the risk of death associated with hepatitis C by 45% and other adverse liver-related complications by 27%, only 4%... View Article
By Annette M. Boyle David Ross, MD, PhD WASHINGTON — New therapies for hepatitis C (HCV) are pouring out of the pharmaceutical pipeline and promising effective treatment with fewer side effects for many of the... View Article
Ramona Gupta, MD By Annette M. Boyle CHICAGO — At the Jesse Brown VAMC in Chicago, a multidisciplinary team approach to evaluating and treating veterans with hepatocellular carcinoma (HCC) has reduced wait times for treatment... View Article
By David Ross, MD, PhD, MBI, director, HIV, HCV and Public Health Pathogens Programs, Office of Public Health/Clinical Public Health Lorenzo L. McFarland, DHA, MSW, PMP, senior manager, Public Health Program, HIV, Hepatitis and Public... View Article
“The approval of eltrombopag allows us to pharmacologically increase platelet counts so that we can initiate and maintain treatment in patients who could not otherwise be treated and achieve a sustained virologic response.” — Mitchell... View Article
Annette M. Boyle LOS ANGELES — The approval last year of the first new drugs for treatment of hepatitis C (HCV) in 20 years substantially increased the rate of virologic cure for patients with the... View Article
By Sandra Basu WEST HAVEN, CT — Twice-a-month online sessions hosted by the VA Connecticut Healthcare System are not typical telemedicine initiatives in which clinicians provide care to individual patients over electronic media. Instead, hepatitis... View Article
Since its discovery in the early 1980s, hepatitis E has been a potent threat to military forces around the world. At one point, the U.S. military was concerned enough to fund intensive research on a... View Article
Alarmed by a near tripling of the number of veterans developing hepatocellular carcinoma (HCC) during the past five years, VA has strengthened its programs for the prevention, screening and treatment of veterans with hepatitis C... View Article
WEST HAVEN, CONN. — Over the last few years, telemedicine has partially redefined how health care is delivered to patients, especially those who do not live near medical centers. For the most part, it has... View Article
It may be possible to predict a soldier’s infection risks during and after strenuous physical exercise by pre-exercise immune system status or from a blood sample taken at rest, according to a recent study.1 According... View Article
© 2000-2017. All Materials Copyright Marathon Medical Communications, Inc.